Background: Fluoxetine may improve the poststroke emotional disturbances. The purpose of the present study was to evaluate the efficacy of fluoxetine on quality of life (QOL) over time in stroke patients with emotional disturbances. Methods: We studied 152 consecutive stroke patients (mean age, 58 years) who had either poststroke depression (PSD), emotional incontinence (PSEI) or anger proneness (PSAP) at an average of 14 months (range = 3–28) after the onset of stroke. The Korean version of SF-36 was used to assess the QOL. The presence of PSD, PSEI and PSAP was also determined with a standardized questionnaire. The subjects were given either 20 mg/day of fluoxetine (n = 76) or placebo (n = 76) for 3 months. Follow-up evaluations were done at 3, 6 and 12 months after the beginning of the treatment. Results: The score in the mental health domain was significantly higher in the fluoxetine group than in the placebo group at the 3-, 6- and 12-month follow-ups. The scores in the general health (p < 0.05) and social functioning (p < 0.05) domains were also significantly higher in the fluoxetine than in the placebo group at 12 months of follow up even if there was no definitive improvement in PSD, PSEI and PSAP at this time. Conclusions: Fluoxetine is effective in improving QOL, particularly so in the mental health subdomain. Our results suggest that fluoxetine may be used to improve the QOL of stroke patients with emotional disturbances.

1.
Kim JS, Choi-Kwon S: Poststroke depression and emotional incontinence: correlation with lesion location. Neurology 2000;54:1805–1810.
2.
Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier T, Newman RM, Curdue K, Petracca G, Starkstein SE: Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 2000;57:351–359.
3.
Robinson RG: Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003;54:376–387.
4.
Gabaldon L, Fuentes B, Frank-Garcia A, Diez-Tejedor E: Poststroke depression: importance of its detection and treatment. Cerebrovasc Dis 2007;24(suppl 1):181–188.
5.
Kim JS: Pathologic laughter after unilateral stroke. J Neurol Sci 1997;148:121–125.
6.
Tang WK, Chan SSM, Chiu HFK, Ungvari GS, Wong KS, Kwok TCY, Wong KT, Richards PS, Ahuja AT: Emotional incontinence in Chinese stroke patients: diagnosis, frequency, and clinical and radiological correlates. J Neurol 2004;251:865–869.
7.
Davidson R, Putnam KM, Larson CL: Dysfunction in the neural circuitry of emotion regulation – a possible prelude to violence. Science 2000;289:591–594.
8.
Kim JS, Choi-Kwon S, Kwon SU, Seo YS: Inability to control anger or aggression after stroke. Neurology 2002;58:1106–1108.
9.
Kauhanen M, Korpelainen JT, Hiltunen P, Brusin E, Mononen H, Maatta R, Nieminen P, Sotaniemi KA, Myllyla VV: Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke 1999;30:1875–1880.
10.
Van de Weg FB, Kuik DJ, Lankhorst GJ: Post-stroke depression and functional outcome: a cohort study investigating the influence of depression on functional recovery from stroke. Clin Rehabil 1999;13:268–272.
11.
King RB: Quality of life after stroke. Stroke 1996;27:1467–1472.
12.
Kim JS, Choi-Kwon S: Sensory sequelae of medullary infarction: differences between lateral and medial medullary syndrome. Stroke 1999;30:2697–2703.
13.
Jonsson A, Lindgren I, Hallstrom B, Norrving B, Lindgren A: Determinants of quality of life in stroke survivors and their informal caregivers. Stroke 2005;36:803–808.
14.
Kim JS, Choi-Kwon S, Kwon SU, Lee HJ, Park KA, Seo YS: Factors affecting the quality of life after ischemic stroke: young versus old patients. J Clin Neurol 2005;1:59–68.
15.
Aprile I, Piazzini DB, Bertolini C, Caliandro P, Pazzaglia C, Tonali P, Padua L: Predictive variables on disability and quality of life in stroke outpatients undergoing rehabilitation. Neurol Sci 2006;27:40–46.
16.
Morris PLP, Robinson RG, Andrzejewski P, Samuels J, Price TR: Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993;150:124–129.
17.
Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS: Fluoxetine treatment in post-stroke depression, emotional incontinence and anger-proneness: a double-blind placebo-controlled study. Stroke 2006;37:156–161.
18.
Studenski S, Duncan PW, Perera S, Reker D, Lai SM, Richards L: Daily functioning and quality of life in a randomized controlled trial of therapeutic exercise for subacute stroke survivors. Stroke 2005;36:1764–1770.
19.
Dettmers C, Teske U, Hamzei F, Uswatte G, Taub E, Weiller C: Distributed form of constraint-induced movement therapy improves functional outcome and quality of life after stroke. Arch Phys Med Rehabil 2005;86:204–209.
20.
Tibaek S, Jensen R, Lindskov G, Jensen M: Can quality of life be improved by pelvic floor muscle training in women with urinary incontinence after ischemic stroke? A randomised, controlled and blinded study. Int Urogynecol J Pelvic Floor Dysfunct 2004;15:117–123.
21.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
22.
Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473–481.
23.
Nam BH, Lee SW: Testing the validity of the Korean SF-36 health survey. J Korean Soc Health Stat 2003;28:3–24.
24.
Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS: Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovasc Dis 2006;23;103–108.
25.
Spilberger CD, Jacobs G, Russell S, Crane RS: Assessment of anger: the State-Trait Anger-Scale; in Butcher JN, Spielberger CD (eds): Advances in Personality Assessment, vol.2. Hillsdale, Erlbaum Associates, 1983, pp 161–189.
26.
Choi-Kwon S, Choi JM, Kwon SU, Kang DH, Kim JS: Factors that affect the quality of life at 3 years post-stroke. J Clin Neurol 2006;2:34–41.
27.
Suenkeler ICH, Nowak M, Misselwitz B, Kugler C, Schreiber W, Oertel WH, Back T: Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke – relationship to neurological deficit, disability and depression. J Neurol 2002;249:1160–1167.
28.
Choi-Kwon S, Kim HS, Kwon SU, Kim JS: Factors affecting the burden on caregivers of stroke survivors in South Korea. Arch Physic Med Rehabil 2005;86:1043–1048.
29.
Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, Davis SM, Harrison W: Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs. placebo. Arch Gen Psychiatry 2002;59:723–728.
30.
Stahl SM: Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Clin Psychiatry 2000;48:894–901.
31.
Cohen LS, Miner C, Brown E, et al: Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerizes diaries. Obstet Gynecol2002;100:435–444.
32.
Miner C, Brown E, McCray S, et al: Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417–433.
33.
Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup H, Pathak S, Robins M, March J: Functioning and quality of life in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006;45:1419–1426.
34.
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805–809.
35.
Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597–606.
36.
Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995;15:7539–7547.
37.
Dam M, Tonin A, De Boni G, Pizzolato S, Casson M, Ermani U, Frco L, Piron L: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211–1214.
38.
Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F: Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718–729.
39.
Pearlstein TB, Halbreich U, Batzar ED, et al: Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101–109.
40.
Halbreich U, Bergeron R, Yonkers KA, et al: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1213–1229.
41.
Windle V, Corbett D: Fluoxetine and recovery of motor function after focal ischemia in rats. Brain Res 2005;1044:25–32.
42.
Jolkkonen J, Puurunen K, Rantakomi S, Sirvio J, Haapalinna A, Sivenius J: Effects of fluoxetine on sensorimotor and spatial learning deficits following focal cerebral ischemia in rats. Restor Neurol Neurosci 2000;17:211–216.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.